Aerovate Therapeutics, Inc. (AVTE)
After hours:
| Previous close | 20.75 |
| Open | 21.00 |
| Bid | 19.93 x 100 |
| Ask | 20.32 x 200 |
| Day's range | 19.99 - 22.34 |
| 52-week range | 9.41 - 32.42 |
| Volume | |
| Avg. volume | 146,761 |
| Market cap | 583.082M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.87 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.67 |
GuruFocus.comAerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 Shares
Timothy Noyes, the Chief Executive Officer of Aerovate Therapeutics Inc (NASDAQ:AVTE), sold 10,000 shares of the company on April 1, 2024, according to a recent SEC Filing.
GlobeNewswireAerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging P
- GuruFocus.com
Aerovate Therapeutics Inc (AVTE) Reports Increased R&D Expenses and Net Loss in 2023
AVTE's Full-Year Financials Reflect Ongoing Clinical Trial Investments and Intellectual Property Expansion
